Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience
Author:
Publisher
Elsevier BV
Subject
Hepatology
Reference26 articles.
1. The Indian national association for study of the liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the puri recommendations;Kumar;J Clin Exp Hepatol,2014
2. 2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II recommendations;Kumar;J Clin Exp Hepatol,2020
3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
5. Lenvatinib for unresectable hepatocellular carcinoma: the first Indian experience;Kulkarni;GastroHep,2021
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Revolutionizing HCC Treatment: A Promising Multimodal Approach With TACE, SBRT, and Immunotherapy;Journal of Clinical and Experimental Hepatology;2024-05
2. Combination of atezolizumab and bevacizumab in patients with inoperable hepatocellular cancer in real clinical practice;Meditsinskiy sovet = Medical Council;2024-01-17
3. Atezolizumab and Bevacizumab for Treatment of Patients With Unresectable / Non-transplantable Advanced Hepatocellular Carcinoma: A Real-World Single Center Experience from North India;Journal of Clinical and Experimental Hepatology;2024-01
4. 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations;Journal of Clinical and Experimental Hepatology;2024-01
5. Outcomes with atezolizumab and bevacizumab in hepatocellular carcinoma - Real-world data from India;International Journal of Molecular and Immuno Oncology;2023-10-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3